Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Bivalirudin manufacturer?Can lipitor's dosage change cause liver enzyme fluctuations?Defense strategy against generic in niche market?Dabrafenib mesylate when the patent is expiring in india?Can wine consumption affect lipitor's cholesterol lowering ability?
See the DrugPatentWatch profile for Siponimod
What is siponimod and why it matters Siponimod is an oral S1P receptor modulator approved for treating secondary progressive multiple sclerosis (SPMS). It blocks S1P‑1 and S1P‑5 receptors, reducing immune cell trafficking into the central nervous system [1]. The drug was launched by Novartis under the brand name Mayzent in 2019. Who owns the rights to siponimod Novartis holds the core patents for siponimod and has entered licensing agreements with partners in key markets. A 2022 patent list shows claims covering the composition, synthesis, and pharmaceutical use of siponimod, with expiry dates projected to extend into the early 2030s [2]. These patents give Novartis exclusive commercial rights, limiting third‑party API production. Does Dr. Reddy’s currently supply a siponimod API Dr. Reddy’s Laboratories is a global pharmaceutical manufacturer with a broad API portfolio, but the company has not announced a production or supply line for siponimod. Their public disclosures list APIs for drugs such as anti‑cancer agents, antibiotics, and cardiovascular drugs, but siponimod is not mentioned among their offerings [3]. Could Dr. Reddy’s license the API in the future A licensing arrangement would require negotiation with Novartis and approval from regulatory authorities. Given the patent coverage, any such agreement would likely involve royalty payments and a limited exclusivity window. The cost of entering such a partnership would be significant, and the payoff would depend on market penetration in regions where Novartis does not hold a license. What happens if Dr. Reddy’s does not produce it Without a Dr. Reddy’s API, manufacturers of generic siponimod would need to source the drug from Novartis‑licensed producers or develop their own synthetic route that does not infringe existing patents. This could delay generic availability and keep prices high until patents expire. How the patent landscape affects pricing and availability Patents on siponimod give Novartis pricing power until at least the early 2030s. Generic competition is expected only after patent expiry, provided no secondary patents or regulatory hurdles block entry. Even then, the high cost of bioprocessing and the need for extensive clinical data could delay generics. Are there alternative manufacturers for similar drugs Other S1P modulators, such as fingolimod (Gilenya) and ozanimod (Zeposia), are produced by different companies and have earlier patent expiries. These alternatives may be considered by clinicians when siponimod is unavailable, but each drug has distinct efficacy and safety profiles. When could a generic siponimod become available If patents expire around 2032–2034, generic manufacturers might file for approval in the mid‑2030s. The actual launch would depend on regulatory approvals in each market and the completion of requisite bioequivalence studies. Where to find more detailed commercial data Dr. Reddy’s annual reports and Novartis investor releases contain financial details on their specialty drug portfolios. Market research firms publish estimates on the SPMS market size and projected generic penetration timelines. --- Sources [1] https://www.novartis.com/news/press-releases/novartis-gets-approval-siponimod-mayzent [2] https://patents.google.com/patent/US20160338266A1 [3] https://www.drreddys.com/our-capabilities